Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

Creaney, Jenette; Dick, Ian M.; Robinson, B. W.

doi:10.1097/mcp.0000000000000167

Cited by 28 publications

(18 citation statements)

References 32 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD163 + on macrophages), extracellular matrix proteins (e.g. OPN, fibulin-3) and RNA/DNA levels and sequence [56][57][58][59][60]. Although the majority of nucleic acid biomarkers have not yet gained acceptance in clinical practice, analysis of epidermal growth factor receptor (EGFR), EML4-ALK and KRAS mutations have a valid role for the targeted treatment of patients with lung cancer.…”

Section: Biomarkersmentioning

confidence: 99%

Malignant pleural effusion: from bench to bedside

et al. 2016

Self Cite

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field. @ERSpublications This review provides up to date knowledge for malignant pleural effusion covering aspects from bench to bedside http://ow.ly/10w7vN

show abstract

Section: Biomarkersmentioning

confidence: 99%

Malignant pleural effusion: from bench to bedside

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recent findings have documented the significantly altered expression status of humoral fibulin-3 in mesothelioma, thereby highlighting its promising application as a novel biomarker for MPM diagnosis and prognosis [9–18]. Nevertheless, single study often presented with inaccurate and insufficient information due to restrictions from limited sample size and research programs.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Pei¹,

Li²,

Li³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Fibulin-3 has emerged as a promising novel biomarker in conforming or monitoring malignant pleural mesothelioma (MPM). This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. Results manifested that humoral fibulin-3 sustained a pooled sensitivity of 0.62 (95% CI: 0.45–0.77) and specificity of 0.82 (95% CI: 0.73–0.89) in discriminating MPM patients from cancer-free individuals, corresponding to an AUC (area under the curve) of 0.81. For the survival analysis, fibulin-3 expression was not markedly associated with overall survival (OS) time of the MPM patients [HR (hazard ratio): 1.84, 95% CI: 0.75–4.56, P = 0.185]. In the subgroup analyses stratified by test matrix and ethnicity, data revealed that serum-based fibulin-3 examination achieved superior accuracy than plasma-based analysis (sensitivity: 0.77 versus 0.54; specificity: 0.85 versus 0.77; AUC: 0.92 versus 0.69); additionally, testing of fibulin-3 in Europeans retained higher efficacy than those in Americans and Australians. Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification.

show abstract

“…In 2007, serum mesothelin has been reported, for the first time, as a prognostic marker in MPM: high soluble mesothelin level significantly correlates with shorter survival, leading to a poor prognosis (12). Its prognostic value has been strongly debated: many following studies confirmed this association (13-15) but others did not endorse serum mesothelin prognostic significance (26,87). While a recent meta-analysis performed on 579 MPM patients further corroborates the inverse association of serum SMRP concentration with the OS (16).…”

Section: Clinical Implications Of Overexpressed Genes In Mpmmentioning

confidence: 77%

“…In order to better characterize the sensitivity and specificity of SMRP as a biomarker for MPM it should take in consideration that SMRP performance as diagnostic biomarker could be influenced by genetics variants, as show in the recent work by De Santi et al (30) and SNP located in the promoter or in the 3'UTR of MSLN gene could affect protein expression levels (89). SMRPs diagnostic value has been evaluated also in pleural effusion (25,26,29) and it has been observed a higher diagnostic performance in pleural effusion than in serum assessment (22). The need to detect the MPM at the early stages led several authors to investigate whether mesothelin can contribute towards the evaluation of the carcinogenic risk in populations exposed to asbestos: high level of SMRPs have been proposed as a marker for early diagnosis in combination with two epigenetic marker (27) or alone (28).…”

Section: Clinical Implications Of Overexpressed Genes In Mpmmentioning

confidence: 99%

Overexpressed genes in malignant pleural mesothelioma: implications in clinical management

2018

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a very aggressive cancer poorly responsive to current therapies. MPM patients have a very poor prognosis with a median survival of less than one year from the onset of symptoms. The biomarkers proposed so far do not lead to a sufficiently early diagnosis for a radical treatment of the disease. Thus, the finding of novel diagnostic and prognostic biomarkers and therapeutic targets is needed. Gene overexpression has been frequently associated with a malignant phenotype in several cancer types; therefore the identification of overexpressed genes may lead to the detection of novel prognostic or diagnostic marker and to the development of novel therapeutic approaches, based on their inhibition. In the last years, several overexpressed genes have been identified in MPM through gene expression profiling techniques: among them it has been found a group of 51 genes that resulted overexpressed in more than one independent study, revealing their consistency among studies. This article reviews the clinical implications of confirmed overexpressed genes in MPM described so far in literature.

show abstract

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma

Abstract: To date, soluble mesothelin remains the best available biomarker for mesothelioma and a positive result is clinically useful in patients with pleural effusions in whom the diagnosis is uncertain.

Cited by 28 publications

References 32 publications

Malignant pleural effusion: from bench to bedside

Malignant pleural effusion: from bench to bedside

Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis

Overexpressed genes in malignant pleural mesothelioma: implications in clinical management

Contact Info

Product

Resources

About